Biological Factors
Key Democrat to Oppose Biosecure Act, Citing Concerns Over Legislation’s Design and Impact on U.S.-China Biotech Relations
Biosecure Act, U.S.-China relations, biotech restrictions, national security, WuXi Biologics, BGI, Congressional opposition
AstraZeneca Invests $135M in Swedish Biologics Manufacturing Expansion
AstraZeneca, biologics manufacturing, Sweden, expansion, investment
WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat
WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market
Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals
Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency
venBio Secures $528M for Fifth Life Sciences Venture Capital Fund
venBio, life sciences, venture capital, fund closing, biotech startups, biopharmaceuticals
BeiGene CEO Eyes Biologics Deals for New US Innovation Center in New Jersey
BeiGene, biologics, innovation center, New Jersey, deals, CEO, John Oyler
Agilent Technologies Acquires Biovectra for $925 Million to Enhance Biologics and CRISPR Capabilities
Agilent Technologies, Biovectra, Acquisition, Biologics, CRISPR, Contract Development and Manufacturing Organization (CDMO)
Innovent Achieves Another Phase 3 Victory in China for Next-Generation Lilly GLP-1 Drug
Innovent Biologics, Lilly, GLP-1, Mazdutide, Phase 3 Trial, Type 2 Diabetes, Weight Loss, China
Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff
Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions
Samsung Biologics and Baxter Expand Manufacturing Partnership with $223M Deal
Samsung Biologics, Baxter Healthcare, Manufacturing Deal, $223M, Drug Products, 2034